| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | BCLW; BCL-W; PPP1R51; BCL2-L-2 |
| Entrez GeneID | 599 |
| clone | 4G12E6 |
| WB Predicted band size | 20.7kDa |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human BCL2L2 (AA: 6-118) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇涉及BCL2L2(BCL-W)抗体的参考文献摘要：
1. **文献名称**: "BCL-W is a pro-survival member of the BCL-2 family expressed in myeloid malignancies"
**作者**: Gibson L et al.
**摘要**: 该研究通过特异性BCL2L2抗体检测发现，BCL-W在急性髓系白血病细胞中高表达，并验证其通过抑制线粒体凋亡通路促进癌细胞存活的作用，为靶向治疗提供依据。
2. **文献名称**: "Characterization of a novel monoclonal antibody specific for human BCL2L2 (BCL-W) protein"
**作者**: Kim H et al.
**摘要**: 研究团队开发了一种高特异性的抗BCL2L2单克隆抗体，验证了其在免疫印迹(Western blot)和免疫组化(IHC)中的应用，证明其可有效区分BCL-W与其他BCL-2家族蛋白。
3. **文献名称**: "BCL-W inhibition sensitizes colorectal cancer cells to 5-fluorouracil by inducing apoptosis"
**作者**: Zhang Y et al.
**摘要**: 使用BCL2L2抗体敲低BCL-W表达后，结直肠癌细胞对5-氟尿嘧啶的化疗敏感性显著提高，证实BCL-W通过调控Bax/Bak依赖性凋亡通路介导化疗耐药。
4. **文献名称**: "Differential expression of BCL2 family proteins in brain tumors: BCL-W as a predictive biomarker"
**作者**: Morales AA et al.
**摘要**: 通过免疫组化分析发现，BCL-W在胶质母细胞瘤中高表达，且与患者生存率负相关，研究采用商业化BCL2L2抗体验证其作为预后生物标志物的潜力。
以上文献均聚焦于BCL2L2抗体的实验应用，涵盖抗体开发、机制研究及临床转化方向。
The BCL2L2 antibody targets the BCL2-like 2 protein (BCL2L2), also known as BCL-W, encoded by the *BCL2L2* gene. BCL2L2 is a member of the BCL-2 protein family, which regulates mitochondrial apoptosis by balancing pro- and anti-apoptotic signals. Specifically, BCL2L2 functions as an anti-apoptotic protein, binding pro-apoptotic BAX/BAK to prevent mitochondrial outer membrane permeabilization and subsequent caspase activation. It is widely expressed in tissues, with roles in maintaining cell survival under stress, particularly in the nervous system, testes, and gastrointestinal tract. Dysregulation of BCL2L2 is implicated in cancer, where its overexpression contributes to tumorigenesis and chemoresistance by inhibiting therapy-induced apoptosis.
BCL2L2 antibodies are critical tools for studying apoptosis mechanisms and cancer biology. They enable detection of BCL2L2 expression in cells or tissues via techniques like Western blotting, immunohistochemistry, and flow cytometry. Commercially available antibodies vary by clonality (monoclonal/polyoclonal), species reactivity (human, mouse, rat), and application-specific validation. Researchers also use these antibodies to explore therapeutic strategies, such as BH3 mimetics, designed to neutralize anti-apoptotic BCL-2 family proteins. Specificity validation (e.g., using knockout cell lines) is essential due to structural similarities among BCL-2 family members. Overall, BCL2L2 antibodies support advances in understanding cell survival pathways and developing targeted cancer therapies.
×
